{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:10:56Z","timestamp":1750219856221},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41433-020-0802-7","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T12:03:07Z","timestamp":1581336187000},"page":"1489-1490","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy"],"prefix":"10.1038","volume":"34","author":[{"given":"Srinivas R.","family":"Sadda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. 2019;126:576\u201388.","journal-title":"Ophthalmology."},{"key":"802_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00006982-198600620-00003","volume":"6","author":"MM Slusher","year":"1986","unstructured":"Slusher MM. Krypton red laser photocoagulation in selected cases of central serous chorioretinopathy. Retina. 1986;6:81\u20134. Spring-Summer","journal-title":"Retina."},{"key":"802_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","volume":"115","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756\u201365.","journal-title":"Ophthalmology."},{"key":"802_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, VICI trial investigators. et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294\u2013303.","journal-title":"Lancet."},{"key":"802_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1751-7176.2011.00495.x","volume":"13","author":"MJ Bloch","year":"2011","unstructured":"Bloch MJ, Basile JN. Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism. J Clin Hypertens. 2011;13:629\u201331.","journal-title":"J Clin Hypertens"},{"key":"802_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","volume":"39","author":"JH Lee","year":"2019","unstructured":"Lee JH, Lee SC, Kim H, Lee CS. Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy. Retina. 2019;39:127\u201333.","journal-title":"Retina."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0802-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:39Z","timestamp":1684617039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0802-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-0802-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SRS reports honoraria from Amgen, Bayer, Genentech\/Roche, Regeneron, Novartis, Allergan, 4DMT, Heidelberg, Optos, Nidek, Centervue, and Heidelberg Engineering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}